AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16735702
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy containing one course with standard dose and one course with high-dose cytarabine
Trial: 16735702
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy containing two courses with high-dose cytarabine
Trial: 16735702
Drug: Postremission therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postremission therapy by prolonged maintenance
Trial: 16735702
Drug: Postremission therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postremission therapy by busulfan/cyclophosphamide chemotherapy with autologous stem-cell transplantation
Trial: 16735702
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy and postremission therapy
Trial: 11292473
Drug: Outpatient group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient group (self-administered misoprostol)
Trial: 11292473
Drug: Inpatient group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient group (administered misoprostol in hospital)
Trial: 9123740
Drug: Nadir PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadir PSA ≤ 0.1 ng/mL
Trial: 9123740
Drug: Nadir PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadir PSA > 0.1 ng/mL
Trial: 27539689
Drug: DAPT to
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT to monotherapy switch
Trial: 27539689
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy after PCI
Trial: 23540665
Drug: Clopidogrel combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel combined with warfarin
Trial: 25401715
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 to 40 mg/d)
Trial: 15061996
Drug: New method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New method of arsenic trioxide administration (0.16 mg/kg divided into two doses, diluted in 250 ml of 5% glucose, given twice daily by intravenous infusion at 8 drops/min with a 2-3 hour interval)
Trial: 15061996
Drug: Routine method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine method of arsenic trioxide administration (0.16 mg/kg infused intravenously once a day for at most 2 hours)
Trial: 2543283
Drug: R61837, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R61837, given by intranasal spray six times a day, total dose 25 mg, starting 28 hours before virus challenge, continued for 4 days.
Trial: 2543283
Drug: R61837, total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R61837, total dose 36 mg, starting 4 hours before virus challenge, continued for 6 days.
Trial: 2543283
Drug: R61837, intranasal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R61837, intranasal, doses of up to 15 mg/day, given shortly after onset of symptoms.
Trial: 24666170
Drug: Plasma treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma treatment (PlasmaDerm® VU‐2010) 3× per week for 8 weeks
Trial: 24666170
Drug: Plasma treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma treatment (PlasmaDerm® VU‐2010)
Trial: 24273973
Drug: IV group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV group (intravenous injection of 2.5 mg droperidol)
Trial: 24273973
Drug: P6 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P6 group (Neiguan point injection of droperidol)
Trial: 24273973
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 mL 0.9% normal saline injection)
Trial: 21733304
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Ca plus 2 mg Cu and 12 mg Zn
Trial: 21733304
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Ca plus maize starch placebo
Trial: 21733304
Drug: Zn supplementation
RxNorm normalized name: zinc bandage with supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zn supplementation with intakes < 8.0 mg/d
Trial: 21733304
Drug: Zn intakes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zn intakes ≥ 8.0 mg/d
Trial: 21733304
Drug: Mg intakes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg intakes < 237 mg/d, Cu intakes < 0.9 mg/d, Zn intakes < 8.0 mg/d
Trial: 17343005
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or Paroxetine (Western medicinal treatment)
Trial: 9478327
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (50 mg/day, Prontogest, AMSA, Italy)
Trial: 9478327
Drug: Micronized vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized vaginal progesterone (200 mg/day Esolut, Angelini, Italy)
Trial: 8179132
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation with propofol (bolus dose 18 mg over 5.4 s; lockout period 1 min)
Trial: 8179132
Drug: Continuous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol infusion (3.6 mg.kg‐1.h‐1)
Trial: 2966600
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with 0.125% bupivacaine and sufentanil 2 micrograms/ml
Trial: 2966600
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with 0.25% bupivacaine and 0.125% bupivacaine infusion
Trial: 30887868
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg pine bark extract
Trial: 30633368
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg, twice daily for 7 days)
Trial: 26274827
Drug: Combined nutraceutical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nutraceutical containing red yeast rice (Dif1Stat(®), including 5 mg monacolin K) and 610 mg PUFAs
Trial: 26274827
Drug: Phytosterols 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols 1600 mg/die
Trial: 23253886
Drug: Glutamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.4 g/kg/day of 20% solution of N(2)-L-alanyl-L-glutamine)
Trial: 19786383
Drug: MLCT oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLCT oil (25-30 g daily for 8 weeks)
Trial: 19786383
Drug: LCT oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT oil (25-30 g daily for 8 weeks)
Trial: 15046230
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) for localized carcinoma of the prostate
Trial: 9551777
Drug: Hydrocortisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (20 mg orally, twice daily for 10 days)
Trial: 29658070
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBM) with low-level laser irradiation (LLLI)
Trial: 29658070
Drug: Endodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic treatment without PBM (Control group)
Trial: 26354678
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of zidovudine (400 mg)
Trial: 26354678
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of zidovudine (600 mg)
Trial: 26354678
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of zidovudine
Trial: 22619027
Drug: Low-dose hCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hCG (200 IU per day) in late follicular phase
Trial: 22619027
Drug: Standard long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard long protocol with gonadotropin administration (10,000 IU hCG for final maturation)
Trial: 22619027
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group (low-dose hCG)
Trial: 18186581
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment on Zhong‐Ji (CV‐3), Guan‐Yuan (CV‐4) and Qi‐Hai (CV‐6) for 10 days
Trial: 18186581
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no moxibustion treatment)
Trial: 10340104
Drug: Androgen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen therapy for pubertal delay
Trial: 10340104
Drug: Long-term treatments
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatments to alter final adult height
Trial: 7603216
Drug: Enriched wafer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched wafer (3.5 mg beta-carotene, 5.2 mg iron, 7.8 g fat)
Trial: 7603216
Drug: Vegetable group
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable group (3.5 mg beta-carotene, 4.8 mg iron, 4.4 g fat)
Trial: 2196208
Drug: Sucralfate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (4 g per day)
Trial: 2196208
Drug: Sucralfate tablets
RxNorm normalized name: Sucralfate Tablets
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate tablets (2 g per day)
Trial: 31764511
Drug: Oral 3000
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 3000 IU/d retinol for 8 weeks
Trial: 31764511
Drug: Oral 6000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 6000 IU/d retinol for 8 weeks
Trial: 28320537
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen acid (Advil)
Trial: 28320537
Drug: 512 mg
RxNorm normalized name: chromic chloride 0.00512 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 512 mg ibuprofen sodium dihydrate (Advil Sodium)
Trial: 23194830
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (rTMS applied to the DLPFC; 10 sessions; 1 session a day; frequency = 10 Hz; intensity = 110% of motor threshold)
Trial: 23194830
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (sham coil)
Trial: 19246724
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg oral dose
Trial: 11701404
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% azelaic acid cream plus oral minocycline
Trial: 11701404
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% azelaic acid cream (maintenance therapy)
Trial: 11701404
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin (control during maintenance phase)
Trial: 9331000
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (2-16 mg, single and repeated once-daily doses)
Trial: 29705177
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (n=45): Three daily sets of single-leg standing (1 min/leg/set) and squatting (5-6 repetitions/set).
Trial: 29705177
Drug: Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise and vitamin D group (n=43): Combination of exercise and vitamin D supplementation.
Trial: 7503183
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined replacement therapy (group B): 2 mg of estradiol, 1 mg of estriol, and 1 mg of norethisterone acetate daily for 12 days per month.
Trial: 7503183
Drug: Sequential estrogen-progestogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential estrogen-progestogen replacement therapy (group A): 2 mg of estradiol valerate daily and 5 mg of medroxyprogesterone acetate daily for 12 days per month.
Trial: 2196946
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (trained for 8 weeks, one hour a week, continued exercising twice daily for one year)
Trial: 2196946
Drug: Non-specific counselling
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific counselling (same attendance schedule, no training, just sit and relax twice a day)
Trial: 7381637
Drug: Phenobarbital 5
RxNorm normalized name: phenobarbital 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 5 mg/kg in a single daily dose
Trial: 30477009
Drug: Triplet-based induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet-based induction therapy with Carfilzomib, Lenalidomide, and Dexamethasone followed by Lenalidomide maintenance therapy
Trial: 23295472
Drug: Low-frequency transcutaneous
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency transcutaneous electrical nerve stimulation (LF-TENS) for 30 minutes daily for 10 days
Trial: 23295472
Drug: Sham TENS
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham TENS for 30 minutes daily for 10 days
Trial: 12926339
Drug: Systemic hemostatic
RxNorm normalized name: Other systemic hemostatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic hemostatic therapy, antisecretory drugs, methods of endoscopic hemostasis
Trial: 9378690
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (75-225 mg) once daily
Trial: 29949328
Drug: Tongkuaixiao ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongkuaixiao ointment (TKXO)
Trial: 21992858
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D (1000 IU for <1 year and 2000 IU for >1 year) once a day for 5 days
Trial: 21992858
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D (1000-2000 IU per day for 5 days)
Trial: 15811151
Drug: Complete sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete sequential video
Trial: 12723743
Drug: Ibuprofen lysine
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen lysine (10, 5, and 5 mg/kg) at 24-hour intervals
Trial: 12723743
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg at 12-hour intervals)
Trial: 12723743
Drug: Ibuprofen (prophylaxis)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (prophylaxis)
Trial: 10229431
Drug: Active nonsteroidal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nonsteroidal antiinflammatory drugs (n=352)
Trial: 8522712
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (525 mg/24 h)
Trial: 8522712
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (1,050 mg/24 h)
Trial: 8522712
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (2,100 mg/24 h)
Trial: 27828927
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg ketamine administered intravenously during ECT under propofol anesthesia
Trial: 27828927
Drug: Isovolumetric placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolumetric placebo (normal saline) administered during ECT under propofol anesthesia
Trial: 9728672
Drug: SSRIs (fluvoxamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (fluvoxamine, fluoxetine, paroxetine, sertraline) at recommended daily dosages for 6 weeks
Trial: 7645712
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy by facemask
Trial: 2520418
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (5 mg/kg body weight)
Trial: 2520418
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine and placebo
Trial: 1092276
Drug: Monthly sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulphadoxine-pyrimethamine
Trial: 30120600
Drug: Sumatriptan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (2 x 50 mg)
Trial: 24578607
Drug: Cervical interlaminar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical interlaminar epidural injections of local anesthetic (0.5% lidocaine, 4 mL) mixed with 1 mL or 6 mg of nonparticulate betamethasone
Trial: 20660280
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A (HD-VA) supplement (209.8 micromol; 60 mg)
Trial: 20660280
Drug: Stable isotope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable isotope (SI)-labeled vitamin A (17.5 micromol; 5 mg)
Trial: 18355327
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus 1 OAD
Trial: 18355327
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus >1 OAD
Trial: 18355327
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (both groups)
Trial: 9438978
Drug: 3 capsules
RxNorm normalized name: Xymogen Medcaps T3 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules of green tea extract (225 mg EGCg, 7.5 mg EGC)
Trial: 9438978
Drug: 5 capsules
RxNorm normalized name: Xymogen Optimag 125 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 capsules of green tea extract (375 mg EGCg, 12.5 mg EGC)
Trial: 9438978
Drug: 7 capsules
RxNorm normalized name: Menaquinone-7 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 capsules of green tea extract (525 mg EGCg, 17.5 mg EGC)
Trial: 2773967
Drug: Orgotein (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgotein (8 mg to 32 mg) administered as an intra-articular injection once a week for three weeks
Trial: 2773967
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as an intra-articular injection once a week for three weeks
Trial: 31408137
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP goal < 120 mm Hg, n=355)
Trial: 31408137
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP goal < 140 mm Hg, n=315)
Trial: 31408137
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP goal < 120 mm Hg)
Trial: 31408137
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP goal < 140 mm Hg)
Trial: 24367678
Drug: Nevirapine-based antiretroviral
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine-based antiretroviral therapy
Trial: 21310350
Drug: Apical resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apical resection at 90° angle with ultrasonic preparation and MTA obturation (Group 2)
Trial: 21310350
Drug: Apical resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apical resection at ∼45° angle with ultrasonic preparation and MTA obturation (Group 4)
Trial: 15163773
Drug: PSA level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA level 0.5 ng/mL or less